In Vivo Eradication of a Rituximab-Resistant Human CD20+ B Cell Lymphoma by Rituximab-CpG Oligodeoxynucleotide Conjugate Is Mediated by Natural Killer Cells and Complement

被引：0
|
作者：
Betting, David J. [1 ]
Kafi, Kamran [1 ]
Yamada, Reiko E. [1 ]
Steward, Kristopher K. [1 ]
Olafsen, Tove [2 ]
Wu, Anna M. [2 ]
van Rooijen, Nico [3 ]
Timmerman, John M. [1 ]
机构：
[1] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA
[2] Univ Calif Los Angeles, Dept Mol & Med Pharmacol, Crump Inst Mol Imaging, Los Angeles, CA 90095 USA
[3] Vrije Univ Amsterdam, Fac Med, Dept Mol Cell Biol, Amsterdam, Netherlands
来源：
BLOOD | 2009年 / 114卷 / 22期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：302 / 302
页数：1
相关论文
共 50 条
  • [21] Tumour targeting and radiation dose of radioimmunotherapy with 90Y-rituximab in CD20+ B-cell lymphoma as predicted by 89Zr-rituximab immuno-PET: impact of preloading with unlabelled rituximab
    Kristoff Muylle
    Patrick Flamen
    Danielle J. Vugts
    Thomas Guiot
    Ghanem Ghanem
    Nathalie Meuleman
    Pierre Bourgeois
    Bruno Vanderlinden
    Guus A. M. S. van Dongen
    Hendrik Everaert
    Mélanie Vaes
    Dominique Bron
    European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42 : 1304 - 1314
  • [22] Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis
    Golay, J
    Zaffaroni, L
    Vaccari, T
    Lazzari, M
    Borleri, GM
    Bernasconi, S
    Tedesco, F
    Rambaldi, A
    Introna, M
    BLOOD, 2000, 95 (12) : 3900 - 3908
  • [23] Effects of complement and serum IgG on rituximab-dependent natural killer cell-mediated cytotoxicity against Raji cells
    Li, Yang
    Huang, Ke
    Liu, Ling
    Qu, Yuhua
    Huang, Yan
    Wu, Yanfeng
    Wei, Jing
    ONCOLOGY LETTERS, 2019, 17 (01) : 339 - 347
  • [24] In Vivo Efficacy of Anti-CD20-Interferon-Gamma Fusion Protein Against Syngeneic B Cell Lymphoma Is Mediated By Natural Killer Cells
    Vasuthasawat, Alex
    Yamada, Reiko E.
    Trinh, Kham R.
    Rokni, Neiki
    Morrison, Sherie L.
    Timmerman, John M.
    BLOOD, 2019, 134
  • [25] Standard International Prognostic Index Remains a Valid Predictor of Outcome for Patients With Aggressive CD20+ B-Cell Lymphoma in the Rituximab Era
    Ziepert, Marita
    Hasenclever, Dirk
    Kuhnt, Evelyn
    Glass, Bertram
    Schmitz, Norbert
    Pfreundschuh, Michael
    Loeffler, Markus
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (14) : 2373 - 2380
  • [26] No evidence of rebound MS disease activity with presence of CD20+ T cells at B-cell reconstitution after treatment with rituximab
    Ruffin, N.
    Asplund-Hogelin, K.
    Khademi, M.
    Al Nimer, F.
    Piehl, F.
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 351 - 351
  • [27] Genetically engineered natural killer (NK) cell immunotherapy for poor risk B-cell (CD20+) leukemia and lymphoma (L/L)
    Chu, Yaya
    Ayello, Janet
    Hochberg, Jessica
    Murphy, James
    Stier, Andrew
    Cairo, Mitchell S.
    CANCER RESEARCH, 2012, 72
  • [28] An anti-C3b(i) mAb enhances complement activation, C3b(i) deposition, and killing of CD20+ cells by rituximab
    Kennedy, AD
    Solga, MD
    Schuman, TA
    Chi, AW
    Lindorfer, MA
    Sutherland, WM
    Foley, PL
    Taylor, RP
    BLOOD, 2003, 101 (03) : 1071 - 1079
  • [29] CD20-Negative Phenotypic Change In B-Cell Lymphoma Cells After Using Rituximab: Possibility of a Particular Clinicopathologic Phenomenon Post-Rituximab Extranodal CD20-Negative Lymphoma
    Tomita, Akihiro
    Tokunaga, Takashi
    Iriyarna, Chisako
    Shimada, Kazuyuki
    Hiraga, Junji
    Sugimoto, Takumi
    Kiyoi, Hitoshi
    Nakamura, Shigeo
    Kinoshita, Tortiohiro
    Naoe, Tomoki
    BLOOD, 2010, 116 (21) : 1184 - 1184
  • [30] Rituximab and bendamustine in patients with CD20+ diffuse large B-cell lymphoma not eligible for cyclophosphamide, doxorubicin, vincristine and prednisone-like chemotherapy
    Walter, Eva
    Schmitt, Thomas
    Dietrich, Sascha
    Ho, Anthony
    Witzens-Harig, Mathias
    LEUKEMIA & LYMPHOMA, 2012, 53 (11) : 2290 - 2292
12345